Pharma Times

OCTOBER 16, 2023

SOTIO will gain access to Synaffix’s three ADC technologies - News - PharmaTimes

127

127

BioTech 365

SEPTEMBER 17, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ESMO: Daiichi unveils first early peek at next-gen ADC as analysts see strong data against rivals.ESMO: Daiichi unveils first early peek at next-gen ADC as analysts see … Continue reading →

Research 40

Research 40

BioTech 365

JUNE 18, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Bristol Myers pays $650M for rights to Eisai’s phase 1 ADC.Bristol Myers pays $650M for rights to Eisai’s phase 1 ADC ntaylor Fri, 06/18/2021 – 04:21 from … Continue reading →

Research 40

Research 40

BioTech 365

NOVEMBER 20, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ADC gets priority review for anti-CD19 blood cancer drug.ADC gets priority review for anti-CD19 blood cancer drug ntaylor Fri, 11/20/2020 – 08:19 from FierceBiotech: Biotech [link].

Drugs 40

Drugs Research 40

BioTech 365

NOVEMBER 5, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Merck inks $2.8B VelosBio buyout to snag anti-ROR1 ADC ntaylor Thu, 11/05/2020 – 07:57 from FierceBiotech: Biotech [link]. VelosBio buyout to snag anti-ROR1 ADC.Merck inks $2.8B

Research 40

Research 40

BioTech 365

MARCH 18, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Pfizer ships out two cancer ADCs alongside its tech platform to Pyxis Oncology, and its familiar CEO.Pfizer ships out two cancer ADCs alongside its tech platform to … Continue reading →

Research 40

Research 40

Pharma Times

JUNE 1, 2023

Synaffix’s technology platform is intended to enhance and extend Lonza’s integrated ADC services - News - PharmaTimes

Development 113

Development 113

BioTech 365

SEPTEMBER 14, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Merck to pay Seattle Genetics $1.6B to ally on breast cancer ADC ntaylor Mon, 09/14/2020 – … Continue reading → to ally on breast cancer ADC.Merck to pay Seattle Genetics $1.6B

Genetics 40

Genetics Research 40

Drug Discovery World

APRIL 12, 2024

News round-up for 8-12 April by DDW Digital Content Editor Diana Spencer. The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so our Friday round-up focuses on drug discovery in oncology.

Drugs 52

Drugs Genetic Engineering Immune Response Engineer 52

Drug Discovery World

SEPTEMBER 29, 2023

News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. The top stories: €27.3M to advance monoclonal antibody for autoimmune diseases AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital.

In-Vivo 52

In-Vivo Drugs Antibody Clinical Trials 52

Drug Discovery World

DECEMBER 22, 2023

News round-up for 18-22 December by DDW Digital Content Editor Diana Spencer. There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer.

Drugs 52

Drugs Antibody FDA Approval Clinical Trials 52

Drug Discovery World

OCTOBER 27, 2023

News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer. My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Drugs 52

Drugs Antibody Vaccination Vaccine 52

Drug Discovery World

MARCH 10, 2023

News round-up for 6-10 March by DDW Digital Content Editor Diana Spencer. Company launches ADC Phase I trial in solid tumours Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2.

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials Drugs 52

XTalks

FEBRUARY 22, 2024

Pending full approval, datopotamab deruxtecan, developed by both companies, could mark a significant milestone as the first TROP2-directed antibody-drug conjugate (ADC) for patients with non-small cell lung cancer (NSCLC). TROP2 is a protein that is widely present in most tumors associated with NSCLC. “We How Does Datopotamab Deruxtecan Work?

Antibody 59

Antibody Clinical Trials Clinical Trials Trials 59

BioTech 365

MAY 18, 2021

DGAP-News: Defence Therapeutics Inc. / CSE: DTC FSE: DTC PRESS RELEASE DEFENCE THERAPEUTICS, STRONG THERAPEUTICS PIPELINE: ADC’s, CANCER AND COVID VACCINES Vancouver, BC, Canada, … Continue reading → Key word(s): Miscellaneous 18.05.2021 / 08:30 The issuer is solely responsible for the content of this announcement.

Vaccination 40

Vaccination Vaccine 40

pharmaphorum

JANUARY 12, 2022

AZ also bought into the second of Daichi Sankyo’s three ADCs – a TROP2-targeted candidate for lung, breast and other cancers called datopotamab deruxtecan (Dato-DXd) – for $1 billion upfront in 2020 with a total value of up to $6 billion. The post Daiichi Sankyo says Plexxikon R&D unit will close down appeared first on.

Drugs 86

Drugs Sales Antibody Marketing 86

Pharmaceutical Technology

SEPTEMBER 2, 2022

The first anti-BCMA product to enter the R/R market was GlaxoSmithKline’s antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin-blmf), gaining FDA approval in 2020.

Antibody 147

Antibody Sales FDA Approval Production 147

pharmaphorum

SEPTEMBER 9, 2022

At this year’s ASCO congress, news that Trodelvy (sacituzumab govitecan) failed to have a significant impact on overall survival (OS) in this form of breast cancer weighed heavily on Gilead, as the Trop2-targeting antibody-drug conjugate (ADC) is central to its plans to grow in oncology.

HR 52

HR Hormones Trials Sales 52

Drug Discovery World

JULY 4, 2023

According to the Financial Times , Credit Suisse analysts said that they had expected investor disappointment at the news because of “high expectations for a positive clinically-meaningful result”. The companies say the trial will continue as planned to assess OS with greater maturity.

Antibody 52

Antibody Trials Engineer Drugs 52

Drug Discovery World

APRIL 8, 2024

.” Innovent Biologics Innovent Biologics presented preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline. ADC for treating solid tumours’ demonstrated Claudin 18.2-specific

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

pharmaphorum

DECEMBER 2, 2022

Following the news of two lecanemab-related deaths reported on the eve of the Clinical Trials on Alzheimer’s Disease (CTAD) 2022 conference, Eisai has now presented the full results from its phase 3 confirmatory Clarity AD study for early Alzheimer’s disease and published them in the New England Journal of Medicine (NEJM).

Trials 57

Trials Clinical Trials Clinical Trials Medicine 57

pharmaphorum

JUNE 20, 2022

On the WSJ Merck/Seagen story, while it's great to hear news about any potential M&A or BD, there is some bad news in there. It says Merck has hesitation about whether a deal could make it through FTC. It shows this is in fact a real issue holding some corners of biotech back. — Brad Loncar (@bradloncar) June 17, 2022.

Sales 103

Sales Marketing Drugs Licensing 103

pharmaphorum

MAY 27, 2022

The results suggest glofitamab could be an effective companion to Roche’s CD79b-directed antibody-drug conjugate (ADC) Polivy (polatuzumab vedotin) which was approved in the EU earlier this week for previously untreated DLBCL and has been tipped to become a $2 billion-plus blockbuster.

Antibody 67

Antibody Sales Trials Development 67

Delveinsight

JULY 28, 2020

Daiichi’s DS-1062 , a trophoblast cell-surface antigen 2 (TROP2) directed DXd antibody-drug conjugate (ADC) is currently in Phase I clinical trial for multiple cancer types including the majority of non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Daiichi holds exclusive rights to the drug in Japan.

Gene Therapy 52

Gene Therapy Trials Gene Vaccination 52

pharmaphorum

FEBRUARY 21, 2022

AZ’s head of oncology R&D Susan Galbraith said the outcome was “historic news” that has the potential to “reshape how breast cancer is classified and treated.” billion to Daiichi Sankyo if all the ADC’s development and sales objectives are achieved. AZ paid a hefty $1.4

Trials 129

Trials Sales Hormones Drugs 129

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim aims to use these antibodies to direct therapeutic effector mechanisms such as antibody-drug conjugates (ADCs) and T-cell engagers exclusively to tumor cells, and to that end develop a range of highly targeted cancer treatments. For ongoing news, visit www.a-star.edu.sg. star.edu.sg. Source link: [link].

Antibody 52

Antibody Licensing Licensing Development 52

pharmaphorum

DECEMBER 15, 2022

Here are the key details of those appointments: ADC Therapeutics (makers of antibody-drug conjugates starting with Zynlonta) appointed Kristen Harrington-Smith as chief commercial officer and Peter Graham as chief legal officer. Check out our other roundups for agency, consultant, investor, and supplier hiring news.

Sales 52

Sales In-Vitro Antibody Drug Delivery 52

STAT News

DECEMBER 5, 2022

… Johnson & Johnson said it does not intend to make an offer for Horizon Therapeutics, days after the developer of medicines for rare autoimmune and inflammatory diseases revealed it was in talks with the company , Bloomberg News writes. regulatory approval, Bloomberg News says.

Insulin 52

Insulin Manufacturing Medicine Drugs 52

Drug Discovery World

NOVEMBER 1, 2023

Datopotamab deruxtecan, Daiichi Sankyo and AstraZeneca The companies shared results from multiple trials of their TROP2 directed DXd antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd). Of 49 patients (41 with CLDN18.2 positive tumours), 28 patients achieved PR, with 23 CR.

Clinical Trials 59

Clinical Trials Clinical Trials Trials HR 59

pharmaphorum

JUNE 7, 2021

The Scottish agency has allowed restricted use of the drug by NHS Scotland, limiting it to patients who are clinically ineligible for or refractory to treatment with Takeda’s Adcetris (brentuximab vedotin), an antibody-drug conjugate (ADC) also used for relapsed CTCL.

Drugs 52

Drugs Licensing Licensing Antibody 52

The Pharma Data

DECEMBER 9, 2020

Below is a roundup of some of this week’s interesting news. The investment will be used to enable Spirea’s ADC therapeutic programs ahead of a significant Seed financing anticipated in 2021. The creation of Overland isn’t the only exciting thing happening for international life sciences companies and organizations.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

pharmaphorum

NOVEMBER 23, 2020

ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a priority review of lead drug Lonca for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin’s lymphoma. ADC Therapeutics is also testing Lonca in earlier lines of therapy.

Drugs 52

Drugs Antibody Trials Medicine 52

Drug Discovery World

APRIL 12, 2024

Enhertu is a specifically engineered HER2 directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca. The ADC is approved with boxed warnings for interstitial lung disease (ILD)/pneumonitis and Embryo-Fetal toxicity. “As

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

Drug Discovery World

MARCH 7, 2024

The merged pipeline features an antibody-drug conjugate (ADC) toolkit with novel payload and linker technologies. By combining chemotherapy with immunotherapy strategies, the company aims to develop new solutions for cancer patients. In addition, the programme includes a novel pre-clinical ADC candidate targeting TROP-2.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

XTalks

NOVEMBER 16, 2022

has won US Food and Drug Administration (FDA) approval for its antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer. Elahere is the first ADC approved for platinum-resistant disease and ImmunoGen’s first drug approval. ImmunoGen Inc. Elahere targets FR?

FDA Approval 98

FDA Approval Antibody Drugs Trials 98

pharmaphorum

NOVEMBER 7, 2022

In this new segment from pharmaphorum, we collect the most significant hirings, firings, and recruitment stories from across the industry. This month, we highlight new appointments from Lumeris, Lineage Cell Therapeutics, 1910 Genetics, and ADC Therapeutics. . ” Kristen Harrington-Smith, ADC Therapeutics .

Life Science 97

Life Science Genetics Business Development Marketing 97

Drug Discovery World

DECEMBER 27, 2023

There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer. You can listen below, or find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

FDA Approval 52

FDA Approval Antibody Drugs Trials 52